Screener
Veradermics MANE Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Veradermics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands, except share and per share amounts) | As of March 31, 2026 | As of December 31, 2025 |
|---|---|---|
| Accounts payable | $1,071 | $2,126 |
| Accrued expenses | 5,606 | 6,979 |
| Other current liabilities and lease liabilities | 39 | 47 |
| Total current liabilities | 6,716 | 9,152 |
| Lease liabilities - non-current | — | 4 |
| Total liabilities | 6,716 | 9,156 |
| Commitments and contingencies (Note 8) | ||
| Redeemable convertible preferred stock: |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics's total current liabilities?
- Veradermics (MANE) reported total current liabilities of $6.72M in Q1 2026.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Veradermics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude